San Francisco’s Frontier Tower transforms urba
Author: Michael
Rejuvenate Biomed to study how metformin-galanta
New paper proposes tackling aging organ by organ
Natural endocrine therapy is designed to help re
Startup targets developmental biology’s ‘Alp
Exclusive investor event brings together scienti
Longevity field hails ‘landmark step’ as US
Targeting toxic fibrin deposits, startup seeks t
New data suggests treatment with Wegovy offers ‘remarkable’ cardioprotective effects – before significant weight loss occurs. This week, Danish pharma giant Novo Nordisk announced new data highlighting the early cardiovascular benefits of Wegovy at the European Congress of Obesity. The company presented a secondary analysis from the Phase 3 SELECT trial, which revealed that Wegovy reduced the risk of major adverse cardiovascular events – including cardiovascular death and non-fatal heart attacks – by 37% compared with placebo within the first three months of treatment. Within six months, the risk of death from cardiovascular disease was halved, and the likelihood of…
As the clinical phase begins, Peter Diamandis ou